Multi-drug attribution is the process of determining which drug or drugs in a combination regimen most likely caused a given adverse event. In oncology, combination therapy is the standard of care: FOLFOX, FOLFIRI, carboplatin and paclitaxel, checkpoint inhibitor combinations, antibody-drug conjugates, CAR-T plus bridging chemotherapy. When fatigue, neutropenia, or hepatic injury occurs, attributing it correctly is the foundation of dose modification, SAE narrative writing, and downstream pharmacovigilance signal detection.
Interactive demo
Try Burna right now, no sign up required.